The issue in Association for Molecular
Pathology (AMP) et al. v. Myriad Genetics, Inc.(Myriad), et al., is
whether a corporation can patent a human gene. The gene is question
may hereafter be known as the Angelina Jolie gene. That's a better
name than BCA1/2, to which it is referred by geneticists. Jolie
discovered through an analysis of her chromosomes that she possessed
mutations of this gene that are a strong positive indicator for
breast cancer and ovarian cancer.
The case was brought by AMP against
Myriad. AMP sought to use the Jolie gene for treatment but discovered
that Myriad had taken out a patent on the gene. Myriad's fee for use
was very high. AMP (and the other complainants) challenged the
constitutionality of such a patent.
Under the law, patents can only be
issued for materials not found in nature. The US Patent Office (PTO)
issued a patent on Myriad's representation that the removal of the
gene from a chromosome in which it is found in the human body
rendered it somehow “not found in nature”. This logic would make
it possible to patent a branch by removing it from a tree, since
branches do not exist in nature except on a tree. Myriad claimed that
the severing of connections to the rest of the chromosome made the
gene patentable. The PTO agreed with Myriad's lawyers in their
pursuit of this dubious patent.
Several commenters have complained
about the technical complexity of the Court's written decision. I
find this odd because most SCOTUS decisions are littered with
legalese that is incomprehensible to the average college graduate.
The laws of a country should be understood by its people.
Antonin Scalia (in a separate
1-paragraph, concurring opinion) also objected to the scientific
terms included in the Court's opinion, written by his longtime
collaborator on the Court, Justice Thomas. Scalia claims that he is
unable to affirm the technical details of the opinion by his own
knowledge or even his own belief.
Scalia made a good point here, but he
failed to recuse himself because of his confessed ignorance of
science. At least he admits his ignorance. Yet in the next sentence
he says that, while BCA1/2 is not patentable because it is not found
in nature, cDNA is patentable because it is not. Scalia says he has
no knowledge of the science, nor even a belief. He therefore cannot
have an educated opinion about the subject matter of this case.
CDNA is a material that scientists
produce from DNA. Its production is somewhat like the mathematical
determination of the square root of a number. Starting with the DNA,
a scientist takes a number of well-understood steps to produce a
cDNA, or complementary DNA. Just as there is only one square root for
a real number, there is only one cDNA for a human gene segment.
The patent office does not grant
patents for the square root of two, for example, nor for the process
by which we obtain the square root of two. These are the building
blocks of mathematics, without which there can be no progress in
mathematics. Yet SCOPUS reaffirms here that a compound that stands in
the path of further research can be patented, thus stifling progress.
The true importance of this decision
was immediately recognized by journalists. Thousands, perhaps
millions, of women who could not afford the extortionate prices
charged by Myriad for cancer screening, may now be rescued from an
early grave. The US is a country of laws, but it is a country of
people first. We cannot condone business practices that result in the
enrichment of a single corporation at the expense of human lives
being needlessly lost.
No comments:
Post a Comment